newsfilter
← Latest News
Business Wire·

Innate Pharma Reports Full Year 2025 Financial Results and Business Update

Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) is planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation, including pharma